Picture of GeneDx Holdings logo

WGS — GeneDx Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

GeneDx Holdings Corp expected to post a loss of 67 cents a share - Earnings Preview

* GeneDx Holdings Corp  WGS.OQ   WGS.O  is expected to show
a rise
in quarterly revenue when it reports  results on April 29 for
the period ending March 31 2024
    * The Stamford Connecticut-based  company is expected to
report a
14.7% increase in revenue to $49.463 million from $43.14 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for GeneDx Holdings Corp is
for a
loss of 67 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for GeneDx
Holdings
Corp is $12.50​, above​ its last closing price of $11.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.64       -0.75      -0.69     Beat    8.4
 Sep. 30 2023  -1.28       -1.31      -0.82     Beat    37.4
 Jun. 30 2023  -1.41       -1.31      -1.64     Missed  -24.9​
 Mar. 31 2023  -1.36       -2.14      -2.44     Missed  -14.2
 ​​Dec.        -4.84       -5.28      -8.25     Missed  -56.2
 31 2022                                                
 Sep. 30 2022  -6.91       -7.01      -6.60     Beat    5.9​
 Jun. 30 2022  -6.61       -6.93      -8.25     Missed  -19
 Mar. 31 2022  -10.54      -10.19     -10.23    Missed  -0.4
 This summary was machine generated April 26 at 22:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on GeneDx Holdings

See all news